Physician profile
Ted E Barber
NPI 1568460111
$24,873.15
in general payments reported to CMS, 2019-2025
68 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,600 · 2020: $4,886 · 2021: $7,278 · 2022: $5,469 · 2023: $2,945 · 2024: $384 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,639 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,638.84 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,589.38 | 2019-2023 | |
| Biogen, INC. | $1,669.46 | 2019-2023 | Tysabri, Vumerity, Spinraza |
| Amgen INC. | $1,251.80 | 2019-2023 | Aimovig |
| Emd Serono, INC. | $1,247.74 | 2019-2025 | Mavenclad |
| Abbvie INC. | $1,197.41 | 2019-2025 | Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,072.81 | 2019-2023 | |
| Sk Life Science, INC. | $865.88 | 2020-2023 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $811.00 | 2019-2023 | Austedo, Austedo Xr |
| Allergan, INC. | $732.25 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $732.03 | 2019-2023 | Ultomiris, Soliris |
| Supernus Pharmaceuticals, INC. | $626.33 | 2019-2022 | |
| Csl Behring | $601.96 | 2019-2023 | Hizentra |
| Ucb, INC. | $594.21 | 2019-2023 | Briviact, Fintepla |
| Acadia Pharmaceuticals INC | $576.96 | 2019-2024 | Nuplazid |
| Acorda Therapeutics, INC | $572.18 | 2019-2023 | Ampyra, Inbrija |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.